Prime Medicine Gets FDA Green Light for Gene Editing Study
The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.
Share
Why It Matters
Prime Medicine got permission to test a new gene editing treatment on people. This shows the FDA thinks the idea is safe enough to try, which is a big early step forward.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.